PathoGenesis Tobi
Executive Summary
A pharmacoeconomic study comparing Tobi (inhaled sterile tobramycin) to pharmacy-compounded formulations of generic intravenous tobramycin has not been conducted nor is such a study planned, the company said ("The Pink Sheet" Oct. 19, p. 9). "The home-compounded version of tobramycin contains phenol and to the extent that it is a safety hazard we could not even get permission to do such a study from the FDA," PathoGenesis commented. Pharmacoeconomic data culled from a subgroup analysis of the two Tobi Phase III trials will be submitted for publication shortly, the company noted